US President Donald Trump has announced reforms aimed at accelerating access to psychedelic drug treatments, marking a significant shift in federal mental health policy.
The move comes after public advocacy from podcaster Joe Rogan, who said he had shared information directly with Trump about the potential benefits of psychedelic therapies, particularly ibogaine, in treating addiction and trauma. Reports indicate Trump responded positively and pushed forward with reforms soon after.
Rogan has claimed that psychedelic treatments can achieve success rates of up to 80 percent in helping people overcome addiction, with some cases reportedly reaching closer to 90 percent with continued treatment.
The reforms aim to fast-track approval of substances such as psilocybin, MDMA and ibogaine, which have shown promise in treating PTSD, depression and substance abuse disorders.
Supporters say the changes could transform mental health care, especially for veterans and those with treatment-resistant conditions. However, experts caution that while results are promising, clinical evidence is still evolving and broader use requires careful oversight.
The policy reflects growing momentum in the US toward expanding access to alternative therapies, though debate continues over safety, regulation and long-term effects.
